Does simvastatin administration disrupt plasma metabolite homeostasis and biotransformation activities in Solea senegalensis

30th New European Society for Comparative Physiology and Biochemistry (ESCPB) Congress, Unraveling complexity: from molecules to ecosystems, 4-7 September 2016, Barcelona.-- 1 pageStatins, among them simvastatin (SV), are a diverse class of pharmaceuticals designed to lower human plasma cholesterol levels (LDL), the cholesterol with the strongest links to vascular diseases, and thus, reducing the risk of heart attack. These lipid regulators are among the most prescribed human pharmaceuticals in western European countries and are present in the aquatic environment at increasing concentrations because of their ability to pass waste-water treatment plants. Despite of its widespread use, many of its toxicokinetics and toxicodynamics aspects in non-target organisms remain unknown. SV is administered as lactone prodrug and generally has higher toxicity than the biologically active acid form of statins. This study aimed to identify the main metabolic responses after an intraperitoneal injection (IP; 10 mg/kg) of SV on a set of physiological markers in juveniles of Solea senegalensis. Blood, muscle and liver samples were collected at 20, 26 and 44 hours after IP injection. None of the plasma metabolites (cholesterol, triglycerides, glucose, lactate, ammonia, osmolality), liver enzymatic activities (EROD, BFCOD, CbE, CAT, GST) nor AChE activity and lipid peroxidation levels in muscle were responsive to SV. However, positive correlations were found between plasma cholesterol and triglyceride levels, liver BFCOD and GST activities, and between lactate levels and CAT activity. Additional research is in progress to unveil other more specific effects of SV in S. senegalensisThis work was financed by the Ministry of Science and Innovation of Spain (ref: CTM2010-16611), and by the Generalitat Valenciana (ref: GV-2014/085-PROMETEO-II)Peer Reviewe